XML 22 R11.htm IDEA: XBRL DOCUMENT

Accounts payable and accrued expenses

6 Months Ended

Jun. 30, 2023

5. Accounts payable and accrued expenses

Accounts payable and accrued expenses at June 30, 2023 and December 31, 2022 consist of the following:


	June 30,		December 31,
	2023		2022
Employee compensation, benefits, and related accruals	$	48,707	$	62,669
Income tax payable		11,149		4,712
Consulting and contracted research		28,522		38,882
Professional fees		3,750		3,093
Sales allowance		71,979		63,787
Sales rebates		108,376		67,355
Royalties		51,720		40,546
Accounts payable		25,741		27,268
Other		8,618		12,054
Total	$	358,562	$	320,366

During the three and six month periods ended June 30, 2023, the Company incurred $8.0 million of restructuring costs from a reduction in workforce in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform. The costs are included in research and development and selling, general, and administrative expenses on the Company’s consolidated statement of operations. As of June 30, 2023, the remaining $6.0 million of accrued restructuring costs are included above within employee compensation, benefits, and related accruals.